Literature DB >> 30403532

Multiparametric MRI Features and Pathologic Outcome of Wedge-Shaped Lesions in the Peripheral Zone on T2-Weighted Images of the Prostate.

Aritrick Chatterjee1, Sevil Tokdemir2, Alexander J Gallan3, Ambereen Yousuf1, Tatjana Antic3, Gregory S Karczmar1, Aytekin Oto1.   

Abstract

OBJECTIVE: This study investigates the multiparametric MRI (mpMRI) characteristics and pathologic outcome of wedge-shaped lesions observed on T2-weighted images.
MATERIALS AND METHODS: Seventy-six patients with histologically confirmed prostate cancer underwent preoperative 3-T MRI before undergoing radical prostatectomy. Two radiologists worked in consensus to mark wedge-shaped regions of hypointensity on T2-weighted images and assess their appearance on apparent diffusion coefficient (ADC) maps (to determine the degree of hypointensity) and dynamic contrast-enhanced (DCE) MRI (DCE-MRI) (to assess whether they showed early enhancement). The pathologic outcome of wedge-shaped lesions was assessed by matching MR images with whole-mount histologic specimens retrospectively. The difference in quantitative ADC values between malignant and benign wedge-shaped lesions was assessed using a t test.
RESULTS: Thirty-five wedge-shaped regions were identified, 12 (34%) of which were found be malignant. Most malignant wedge-shaped regions were highly hypointense (10/12; 83%) on ADC maps and showed early enhancement on DCE-MRI (7/12; 58%). However, benign wedge-shaped lesions were predominantly mildly hypointense (13/23; 57%) on ADC maps and showed no early enhancement (15/23; 65%). Histologic correlates of the benign wedge-shaped regions showed prostatitis (acute inflammation [7/23; 30%] or chronic inflammation [9/23; 39%]), hemosiderin-laden macrophages (6/23; 26%), prominent blood vessels (7/23; 30%), intraluminal blood (6/23; 26%), and nonspecific atrophy (6/23; 26%). The mean (± SD) quantitative ADC value of malignant wedge-shaped regions (1.13 ± 0.11 μm2/ms) was significantly lower (p = 0.0001) than that of benign wedge-shaped regions (1.52 ± 0.27 μm2/ms).
CONCLUSION: This study shows that a greater percentage of wedge-shaped features are malignant than was previously thought. Of importance, mpMRI (specifically, ADC maps) can distinguish between malignant and benign wedge-shaped features.

Entities:  

Keywords:  T2-weighted images; apparent diffusion coefficient; histology; prostate MRI; wedge-shaped lesions

Mesh:

Substances:

Year:  2018        PMID: 30403532      PMCID: PMC6437777          DOI: 10.2214/AJR.18.19742

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  27 in total

1.  Characteristics of PI-RADS 4 lesions within the prostatic peripheral zone: a retrospective diagnostic accuracy study evaluating 170 lesions.

Authors:  Prasad R Shankar; Nicole E Curci; Matthew S Davenport
Journal:  Abdom Radiol (NY)       Date:  2018-08

2.  How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer?

Authors:  Ege Can Serefoglu; Serkan Altinova; Nevzat Serdar Ugras; Egemen Akincioglu; Erem Asil; M Derya Balbay
Journal:  Can Urol Assoc J       Date:  2013-05-13       Impact factor: 1.862

3.  Dynamic Contrast-enhanced MR Imaging Curve-type Analysis: Is It Helpful in the Differentiation of Prostate Cancer from Healthy Peripheral Zone?

Authors:  Barry G Hansford; Yahui Peng; Yulei Jiang; Michael W Vannier; Tatjana Antic; Stephen Thomas; Stephanie McCann; Aytekin Oto
Journal:  Radiology       Date:  2015-01-05       Impact factor: 11.105

4.  Prostate cancer: correlation of MR images with tissue optical density at pathologic examination.

Authors:  L E Quint; J S Van Erp; P H Bland; E A Del Buono; S H Mandell; H B Grossman; P W Gikas
Journal:  Radiology       Date:  1991-06       Impact factor: 11.105

5.  Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology.

Authors:  Sofie Isebaert; Laura Van den Bergh; Karin Haustermans; Steven Joniau; Evelyne Lerut; Liesbeth De Wever; Frederik De Keyzer; Tom Budiharto; Pieter Slagmolen; Hendrik Van Poppel; Raymond Oyen
Journal:  J Magn Reson Imaging       Date:  2012-11-21       Impact factor: 4.813

6.  Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer.

Authors:  Nienke L Hansen; Tristan Barrett; Claudia Kesch; Lana Pepdjonovic; David Bonekamp; Richard O'Sullivan; Florian Distler; Anne Warren; Christina Samel; Boris Hadaschik; Jeremy Grummet; Christof Kastner
Journal:  BJU Int       Date:  2017-11-15       Impact factor: 5.588

7.  Characterization of prostate cancer missed by sextant biopsy.

Authors:  John B Bak; Steve K Landas; Gabriel P Haas
Journal:  Clin Prostate Cancer       Date:  2003-09

Review 8.  Benign Conditions That Mimic Prostate Carcinoma: MR Imaging Features with Histopathologic Correlation.

Authors:  Yu Xuan Kitzing; Adilson Prando; Celi Varol; Gregory S Karczmar; Fiona Maclean; Aytekin Oto
Journal:  Radiographics       Date:  2015-11-20       Impact factor: 5.333

9.  Susceptibility weighted imaging: differentiating between calcification and hemosiderin.

Authors:  Jeam Haroldo Oliveira Barbosa; Antonio Carlos Santos; Carlos Ernesto Garrido Salmon
Journal:  Radiol Bras       Date:  2015 Mar-Apr

10.  Pitfalls in Interpreting mp-MRI of the Prostate: A Pictorial Review with Pathologic Correlation.

Authors:  V Panebianco; F Barchetti; J Barentsz; A Ciardi; F Cornud; J Futterer; G Villeirs
Journal:  Insights Imaging       Date:  2015-09-18
View more
  2 in total

1.  Prostate Imaging-Reporting and Data System: Comparison of the Diagnostic Performance between Version 2.0 and 2.1 for Prostatic Peripheral Zone.

Authors:  Hyun Soo Kim; Ghee Young Kwon; Min Je Kim; Sung Yoon Park
Journal:  Korean J Radiol       Date:  2021-04-09       Impact factor: 3.500

2.  Application Value of Radiomic Nomogram in the Differential Diagnosis of Prostate Cancer and Hyperplasia.

Authors:  Shaogao Gui; Min Lan; Chaoxiong Wang; Si Nie; Bing Fan
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.